Sluggish Biotech Stocks: Five Underlying Factors Plus A Sector Shift?
MegaCap Tech Stocks Take a Big Hit-Volatility Rising in a Sector Shift Market Rotation Supports Overall Market-S&P 500 Stable today up 17% YTD Sluggish Biotech Now Just a Market Performer With IBB up 17% YTD The booming tech sector sold off today with the XLK down over 2%. Harder hit were the...
Rayno Biopharmaceutical Portfolio Update with Biotech Holding: CELG,RHHBY,XBI…Update 11/29 Rotation Day
11/29/17 Market Reversal in Early Trading 11:35a -FAANG sell-off Stocks show a rotation out of technology and into financials and cyclical consumer goods. XLK is down 2.2%, XLV up 0.66%, IBB up 0.42% with large caps holding. 11/28/17 Biotechs Treading Water But Many Good Opportunities Exist...
Biotech Correction: Just a market rotation or slower growth ahead?
Biotech Correction: Sell-Off Has Reached 10% over Three Months Biotechs under pressure-has revenue growth slowed? Technicals-a break through bottom channel. Need a bounce today. Celgene is a bellwether. A buy in the $102 range. Biotech stocks have been weak since Q4 earnings were reported and...
LaNina is Here with First Major West Coast Storm of Season in Coming Days
A LaNina Advisory was Issued on November 9 This weak LaNina generally affects climate as follows: "The outlooks generally favor above-average temperatures and below-median precipitation across the southern tier of the United States, and below-average temperatures and above- median precipitation...
Biotech Hangover: Recent Earnings Feed Caution with No Near Term Catalysts
Biotech Hangover from Earnings Clouds Outlook Healthcare sector (XLV) lagging technology (QQQ) and FAANG stocks. No earnings catalysts until Jan 2018 but Q4 has seen strong seasonality. Technicals rule as sellers predominate. Bull market is intact. On October 16 we posted that Risks were Rising...